SUMMARY
Inhalation of nebulized lignocaine is a wellestablished technique for providing airway anaesthesia prior to awake fibreoptic intubation 1 . Dosage recommendations for nebulization vary from 4 ml of 4% lignocaine solution to 10 ml of 4% lignocaine solution 2 . Previous studies have documented the safety of inhalation of lignocaine from an ultrasonic nebulizer [3] [4] [5] and a pneumatic (compressed gaspowered) nebulizer 6 . It has also been shown that nebulization of lignocaine produces lower plasma lignocaine concentrations than direct spraying of lignocaine onto the airway mucosa 2 . Some anaesthetists use higher dosages of inhaled nebulized lignocaine, i.e. up to 500 mg in adults, to provide improved airway anaesthesia. The aim of this study was to evaluate the safety of inhaled lignocaine via a compressed gas-powered nebulizer using 10% lignocaine solution at a dose of 6 mg/kg, and to assess whether the resulting blood concentrations proved to be low enough to allow further supplemental doses of lignocaine to be administered as required with safety.
PATIENTS AND METHODS
Following institutional Ethics Committee approval and informed consent, ten ASA I volunteers were recruited to the study. The study was undertaken in the operating theatre and all volunteers were seated on a theatre trolley. Electrocardiograph and oxygen saturation monitoring was commenced and antecubital intravenous access secured. A compressed gas-powered nebulization mask (Baxter Airlife Misty-neb) was filled with 10% lignocaine solution (Xylocard 500 mg in 5 ml, Astra Pharmaceuticals) at a dose of 6 mg/kg. The solution was nebulized by an oxygen flow of 6 l/min and subjects were instructed to breathe normally. Venous blood for lignocaine assay was collected at 5, 10, 15, 20, 30 and 40 minutes after commencement of nebulization, using a notourniquet technique. Specimens were separated and stored at -20°C prior to analysis.
Statistical Analysis
Because distributions of lignocaine levels proved to be skewed during the first 20 minutes, medians and box-plots were used to display the time trend of the recorded lignocaine levels. Because the distribution of the peak levels was found to be symmetrical, a Anaesth Intensive Care 1997; 25: [369] [370] [371] Plasma Lignocaine Concentration Following Nebulization for Awake Intubation S. B. PARKES*, C. S. BUTLER †, R. MULLER ‡ t-distribution with 9 degrees of freedom was used to calculate the probabilities exceeding certain lignocaine levels.
RESULTS
Of the ten volunteers, seven were male and three were female. The mean age was 33.0 years (range 26-40) and mean weight was 77.2 kg (range 57-97 kg). Mean time for completion of nebulization was 22.1 minutes (range 16-28 minutes). Table 1 summarizes the original data obtained. A box-plot of plasma lignocaine levels over time is depicted in Figure 1 . The five-minute sample was missed on one volunteer due to malposition of the cannula.
The mean peak plasma lignocaine concentration for these ten subjects was 0.29 mg/l (standard deviation 0.09/median 0.30) and the median duration to reach peak concentration was 30 minutes after commencement of nebulization. A total of 59 separate blood samples were obtained from these ten volunteers, the single highest measurement being 0.45 mg/l. Assuming a t-distribution with 9 degrees of freedom, the probability for a person to exceed a lignocaine blood level of 1.05 mg/l is less than 0.000001 and to exceed 1.6 mg/l is less than 0.0000001. All ten volunteers described an unpleasant taste in association with inhalation of the 10% lignocaine solution. None experienced any symptoms or exhibited any sign of local anaesthetic toxicity.
DISCUSSION
The results of this study show that inhalation of nebulized lignocaine at a dose of 6 mg/kg produces peak plasma lignocaine concentrations which are well below the toxic threshold of 5 mg/l 7 . All subjects in the study were healthy, unpremedicated volunteers. Anticholinergic premedication reduces the dilutional effect which salivary secretions have upon topical or inhaled local anaesthetics, and may therefore produce increased absorption and greater plasma concentrations 8 . Lignocaine is almost exclusively metabolized by the liver, and in patients with significant hepatic disease, metabolism may be decreased and hence plasma concentration may be expected to be higher 9 . Clearance of lignocaine is also decreased in patients with congestive cardiac failure, such patients requiring dosage reductions 2 . This study measured venous lignocaine concentrations. It has been shown that arterial levels usually prove to be slightly higher than venous levels 5 . This difference however is in the order of 20 to 30% and consequently does not affect any stated conclusions.
In this study, although the total dose of lignocaine was 6 mg/kg, only a portion of this dose was actually inspired. The remainder becomes nebulized to the environment. This is in keeping with the very low lignocaine concentrations found. We did not attempt to determine the level of anaesthesia produced with this method of administration. However, the estimated probabilities for a patient to exceed as little as 1.0 or 1.6 mg/l proves that supplemental doses can be administered via the bronchoscope with safety. Even if the estimates are made from just ten patients, the above-mentioned levels are still of an order of magnitude below accepted toxicity limits. Peak =Peak lignocaine concentration. Time=Time to reach peak lignocaine concentration.
FIGURE 1: Box-plot of lignocaine blood levels as mg/l (n=10).
